Cigarette smoking is strongly correlated with onset of lung cancer and statistically more than 90% of lung cancer patients are smokers. However, lung cancer caused by second-hand smoking remains unknown. Nicotine is a major component of cigarettes and exists at high concentrations in the bloodstream of smokers. Nicotine-based products are widely used to aid smoking cessation and to treat patients clinically with chronic pain. Studies have shown that nicotine binds to nicotine acetylcholine receptors (nAChRs) and further activates several mitogen-related signaling pathways in various types of cells including lung epithelial and cancer cells and vascular endothelial cells. The anti-apoptotic activity of Bcl-2 is also induced by nicotine treatment. We demonstrated that nicotine activates Ras and protein kinase C (PKC) pathways, leading to the disruption of cell growth restriction. However, the mechanisms of nicotine in the onset or development of lung cancer remain to be elucidated. Therefore, our long-term objective of the proposal is to study the role of nicotine in lung carcinogenesis. Such study will identify novel components in nicotine-mediated signaling pathways and will help modifying the current usage of nicotine. The central hypothesis of the proposal is that nicotine acts as a potential carcinogen that can mobilize intracellular growth-related signal pathways and antagonize apoptotic signaling, which creates a permissive environment for tumorigenesis.
The specific aims to test the hypothesis are: 1) to investigate the mechanisms of nicotine-mediated cell growth promotion;2) to determine how nicotine exposure perturbs G1 cell cycle checkpoint;3) to study the molecular mechanisms of nicotine-mediated anti-apoptotic action. Mouse or rat lung epithelial and various human lung cancer cells will be used in the proposed experiments. Our understanding of nicotine will not only offer a cautionary stance for the therapeutic use of this compound, but also help developing new stratigies for treating nicotine addiction or chronic pain cessation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Blair, Donald G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Nishioka, T; Luo, L-Y; Shen, L et al. (2014) Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer 110:1785-92
Nishioka, Takashi; Yamamoto, Daisuke; Zhu, Tongbo et al. (2011) Nicotine overrides DNA damage-induced G1/S restriction in lung cells. PLoS One 6:e18619
Nishioka, Takashi; Kim, Hyun-Seok; Luo, Ling-Yu et al. (2011) Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth. Breast Cancer Res 13:R113
Han, Ihn; Jeong, Soo-Jin; Lee, Hyo-Jung et al. (2011) Proteomic analysis of mesenchymal stem-like cells derived from ovarian teratoma: potential role of glutathione S-transferase M2 in ovarian teratoma. Proteomics 11:352-60
Choo, Eun Jeong; Rhee, Yun-Hee; Jeong, Soo-Jin et al. (2011) Anethole exerts antimetatstaic activity via inhibition of matrix metalloproteinase 2/9 and AKT/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol Pharm Bull 34:41-6
Zhou, J; Yang, Z; Tsuji, T et al. (2011) LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene 30:1892-900
Ahn, Quein; Jeong, Soo-Jin; Lee, Hyo-Jung et al. (2010) Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett 298:212-21
Nishioka, Takashi; Guo, Jinjin; Yamamoto, Daisuke et al. (2010) Nicotine, through upregulating pro-survival signaling, cooperates with NNK to promote transformation. J Cell Biochem 109:152-61
Guo, Jinjin; Ibaragi, Soichiro; Zhu, Tongbo et al. (2008) Nicotine promotes mammary tumor migration via a signaling cascade involving protein kinase C and CDC42. Cancer Res 68:8473-81